Light Mode
$3.96 ↓ -0.02 (-0.50%) Trading Down from the previous close of $3.98, $0.34 below the day’s high of $4.30
-6.63 (-62.08%) / 6M
Momentum, market sentiment, and recent alerts
PMN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +941.9%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.